Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -298.60K | -499.40K | -- | -97.80K |
| Total Depreciation and Amortization | -- | 11.50K | 11.30K | -- | 10.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -96.90K | 46.30K | -- | 372.00K |
| Change in Net Operating Assets | -- | 2.30K | -389.30K | -- | 244.90K |
| Cash from Operations | -- | -381.70K | -831.20K | -- | 530.00K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -3.63M | -180.70K | -- | -73.70K |
| Cash from Investing | -- | -3.63M | -180.70K | -- | -73.70K |
| Total Debt Issued | -- | -- | -- | -- | -49.50K |
| Total Debt Repaid | -- | -30.30K | -29.80K | -- | -22.80K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -551.70K |
| Cash from Financing | -- | -22.00K | -21.60K | -- | -445.80K |
| Foreign Exchange rate Adjustments | -- | 3.40K | -4.30K | -- | -1.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -4.03M | -1.04M | -- | 9.40K |